Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816075 | 0.84 | KDM4E (0.68) | KDM4EGAAMAPTPSMB8NAMPT | |
| SCHEMBL6814023 | 0.83 | PSMB8 (0.46) | GAAPSMB8NAMPTCYP17A1BCL2 | |
| SCHEMBL7715855 | 0.82 | MAPT (0.49) | KDM4EGAAMAPTLMNANPSR1 | |
| SCHEMBL6814783 | 0.78 | LMNA (0.64) | GAAPSMB8NAMPTLMNA | |
| SCHEMBL6811054 | 0.74 | NAMPT (0.54) | KDM4EGAAPSMB8NAMPTCYP17A1 | |
| SCHEMBL6814819 | 0.72 | MAPT (0.46) | KDM4EGAAMAPTLMNANPSR1 | |
| SCHEMBL6815330 | 0.71 | ALDH1A1 (0.50) | GAAMAPTPSMB8NAMPTCYP17A1 | |
| SCHEMBL190015 | 0.70 | CA12 (0.45) | PSMB8NAMPTCYP17A1BCL2BECN1 | |
| SCHEMBL27647685 | 0.70 | LCK (0.43) | PSMB8BCL2BECN1 | |
| SCHEMBL6815952 | 0.69 | PPARG (0.43) | KDM4EGAAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | claimed |
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2003-02-20 | — | — | US | disclosed |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-28 | — | — | US | disclosed |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | HAVCR2, CCR6, CXCR6 | KDM4E 2975/4885GAA 3254/4885MAPT 3898/4885 |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | CCR6, HAVCR2, BCOR | KDM4E 1441/4885GAA 2805/4885MAPT 3272/4885 |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | TK1, TPMT, CXCR6 | KDM4E 225/4885GAA 3370/4885MAPT 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.